A Phase 3 interventional study of LDX 30 mg and LDX 50 mg in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Shire. Completed at 45 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 7th largest by enrollment, is one of 9 that started in 2008, is one of 15 in phase 3, and was the 12th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 9 started in 2008.
This study's enrollment of 314 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 17th largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2008, is one of 32 in phase 3, and was the 23rd registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LDX 30 mg
Drug: LDX 50 mg
Drug: LDX 70 mg
Drug: Placebo
Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Also known as: Vyvanse
Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Placebo will be identical to test product.
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
Time frame: Baseline and 1, 2, 3 and 4 weeks
Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: 1, 2, 3 and 4 Weeks
Youth Quality of Life-Research Version (YQOL-R) Total Score
The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.
Time frame: Baseline and 4 weeks
| Milestone | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo |
|---|---|---|---|---|
| Started | 78 | 79 | 78 | 79 |
| Completed | 63 | 66 | 67 | 69 |
| Not completed | 15 | 13 | 11 | 10 |
| Withdrew: Adverse event | 3 | 3 | 4 | 1 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 3 | 1 |
| Withdrew: Lack of efficacy | 4 | 2 | 0 | 4 |
| Withdrew: Sponsor decision | 3 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 2 | 0 |
| Withdrew: Prior vyvanse exposure | 1 | 1 | 0 | 0 |
| Withdrew: Exclusion criteria | 1 | 0 | 0 | 0 |
The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.
| Units on a scale | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks | -18.3 ± 1.25 | -21.1 ± 1.28 | -20.7 ± 1.25 | -12.8 ± 1.25 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| Participants | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | 44 | 53 | 57 | 30 |
The Youth Quality of Life-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often). The YQOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.
| Units on a scale | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo |
|---|---|---|---|---|
| Baseline | 79.3 ± 10.03 | 80.5 ± 10.63 | 78.8 ± 15.38 | 79.2 ± 11.08 |
| 4 Weeks | 81.1 ± 11.09 | 81.3 ± 11.86 | 81.3 ± 14.66 | 81.3 ± 12.16 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisdexamfetamine Dimesylate (LDX) 30 mg | — | 0/78 (0%) | 51/78 (65.4%) |
| LDX 50 mg | — | 0/77 (0%) | 53/77 (68.8%) |
| LDX 70 mg | — | 0/78 (0%) | 56/78 (71.8%) |
| Placebo | — | 0/77 (0%) | 38/77 (49.4%) |
| Event | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo |
|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 29/78 | 21/77 | 29/78 | 2/77 |
| HeadacheNervous system disorders | 9/78 | 13/77 | 12/78 | 10/77 |
| Weight decreasedInvestigations | 3/78 | 7/77 | 12/78 | 0/77 |
| InsomniaPsychiatric disorders | 7/78 | 8/77 | 11/78 | 3/77 |
| IrritabilityGeneral disorders | 6/78 | 2/77 | 8/78 | 3/77 |
| Upper respiratory tract infectionInfections and infestations | 2/78 | 4/77 | 4/78 | 6/77 |
| Dry mouthGastrointestinal disorders | 0/78 | 6/77 | 4/78 | 1/77 |
| DizzinessNervous system disorders | 1/78 | 4/77 | 5/78 | 3/77 |
| NauseaGastrointestinal disorders | 1/78 | 3/77 | 5/78 | 2/77 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/78 | 0/77 | 5/78 | 1/77 |
| Age, Categorical(Participants) | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 78 | 79 | 78 | 79 | 314 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 14.6 ± 1.39 | 14.7 ± 1.29 | 14.4 ± 1.30 | 14.5 ± 1.25 | 14.6 ± 1.31 |
| Sex: Female, Male(Participants) | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 19 | 16 | 34 | 25 | 94 |
| Male | 59 | 63 | 44 | 54 | 220 |
| Region of Enrollment(Participants) | Lisdexamfetamine Dimesylate (LDX) 30 mg | LDX 50 mg | LDX 70 mg | Placebo | Total |
|---|---|---|---|---|---|
| United States | 78 | 79 | 78 | 79 | 314 |
Ran from Oct 2008 to primary completion in Apr 2009, 5 months.
Results were first posted in Feb 2010, 10 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 5 months is below that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →